Researchers examined clinical outcomes and treatment patterns among youths with ADHD, internalizing disorders, and comorbid disruptive mood dysregulation disorder.

From 2021 to 2023, stimulant marketing payments doubled and tripled for physicians and advanced practice clinicians, respectively. The increases were driven in large part by growth in marketing to ...

When child psychiatrists gather, presentations on ADHD almost always orbit around the use of stimulants—methylphenidate and amphetamine in their many formulations. At this year’s Texas Society of ...

The US Food and Drug Administration (FDA) on Thursday opened a public consultation to gather input on the development and evaluation of abuse-deterrent formulations (ADF) of central nervous system ...